



164
CASE D0118 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Stephen C. D'Amico
Type or print name

Signature

7-25-03
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
FEDER ET AL.

APPLICATION NO: 10/067,649

FILED: FEBRUARY 5, 2002

FOR: A NOVEL HUMAN G-PROTEIN COUPLED RECEPTOR,
HGPRBMY14, RELATED TO THE ORPHAN GPCR, GPR73

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

#6
RECEIVED
JUL 30 2003
TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-5289


Stephen C. D'Amico
Agent for Applicants
Reg. No. 46,652

Date: 7-25-03

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0118 NP
APPLICATION NO.
10/067,649
APPLICANT
FEDER ET AL.
FILING DATE
FEBRUARY 5, 2002

Group



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

RECEIVED
JUL 30 2003
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	WO 02/057443	7/25/02	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 02/061087	8/8/02	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO 02/062944	8/15/02	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AP	WO 02/062996	8/15/02	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	NCBI ENTREZ ACCESSION NO. gi 20257196, Masuda, Y. et al., May 21, 2002
AS	NCBI ENTREZ ACCESSION NO. gi NP_620414, Soga, T. et al., April 6, 2003
AT	Parker, R. et al., "Y-receptor-like genes GPR72 and GPR73: molecular cloning, genomic organisation and assignment to human chromosome 11q21.1 and 2p14 and mouse chromosome 9 and 6", Biochimica et Biophysica Acta, Vol. 1491, pp. 369-375 (2000)

EXAMINER


DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.
D0118 NP
APPLICATION NO.
10/067,649
APPLICANT
FEDER ET AL.
FILING DATE
FEBRUARY 5, 2002

Group



(Use separate sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

2AA	Soga, T. et al., "Molecular cloning and characterization of prokineticin receptors", Biochimica et Biophysica Acta, Vol. 1579, pp. 173-179 (2002)
AB	
AC	
AD	
AE	
AF	
AG	
AH	
AI	
AJ	
AK	
AL	
AM	
AN	

RECEIVED
JUL 30 2003
TECH CENTER 1600/2900

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP.609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.